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obtained from Brazilian official price lists. Results: 95,688 hospitalizations were 
identified with total length of stay (LOS) of 336,939 days; deaths and mortality rates 
were 866 and 0.91 respectively.1 The model estimated costs for the inpatient period 
assuming one dressing change every 3 days for MEDIHONEY and AG, considering 
in both cases a similar size. Cost per dressing change was estimated as USD35.80 
and US31.85 for AG and MEDIHONEY, with mean healing time of 53 and 31 days, 
respectively.2 Overall treatment costs were USD4,020,805.30 and USD3,577,169.00 
according to the LOS and USD632.46 and USD329.12 according to MHT/patient for 
AG and MEDIHONEY, respectively. MEDIHONEY-related incremental costs were 
USD31,492,834 indicating a cost-saving proﬁle. Adopting MEDIHONEY as wound 
management protocol would save USD29,025,998 for the 2013/2014-cohort. Clinical 
benefits for use of MEDIHONEY CALCIUM ALGINATE over AG include decreased 
risk of hypersensitivity to compounds, MEDIHONEY treatment is appropriate 
throughout wound healing process and MEDIHONEY does not induce microbial 
resistance.3 ConClusions: MEDIHONEY dressing demonstrates cost-effectiveness 
when compared to AG dressings. These results reinforce the need for evidence-based 
decision making and rational resource allocation; in addition to further studies 
including clinical outcomes data.
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objeCtives: The objective is to develop a full economic evaluation of the cost 
effectiveness of using sacral neurostimulation versus botulinum toxin type A and 
augmentation cystoplasty in the treatment of overactive bladder in Mexico, from 
the perspective of the public health sector. Methods: A systematic literature 
review was conducted to identify articles to extract data on safety and efficacy of: 
sacral neurostimulation, botulinum toxin type A, and augmentation cystoplasty. 
A cost-effectiveness analysis was performed using a Markov model with a time 
horizon of 1 to 5 years. The effectiveness was measured as continence years and 
quality-adjusted life year (QALY). Only direct medical costs were considered, such 
as: medicine, surgery, devices, adverse events, days of hospitalization and labora-
tory studies; an analysis of incremental cost-effectiveness ratio (ICER) and incre-
mental cost-utility (ICU) was performed. To test the model and demonstrate the 
robustness, a probabilistic sensitivity analysis was performed, using Monte Carlo 
simulations. Results: Sacral neurostimulation showed better efficacy with 3.65 
continence years and 3.27 QALY’s with a cost of $279,538.11- The ICER over botuli-
num toxin A was 69,917.92, less than one time the Mexican GDP per capita, for the 
botulinum toxin the cost was 191,143.86 with 2.39 continence years and 2.13 QALY´s; 
for augmentation cystoplasty the cost was $205,049.02 with 3.19 continence years 
and 2.85 QALY’s. The probabilistic sensitivity analysis demonstrated that sacral 
neurostimulation is a cost-effective alternative, despite the modification of all the 
model’s variables. ConClusions: Sacral neurostimulation is a very cost-effective 
alternative for patients in the the public health care system in Mexico, being ICU 
and ICER less than one time the Mexican GDP per capita.
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objeCtives: The severity of the effect in reducing the risk of sudden cardiac 
death has a significant positive impact on the forecast as a whole and significantly 
reduces overall mortality rate among different categories of cardiology patients. 
Meanwhile, it imposes a significant burden on the healthcare budget of the Republic 
of Kazakhstan. Due to the fact that the CD’s implantation is an expensive method 
of treatment, the authors conducted a review of existing studies on the cost-effec-
tiveness of the CD in the application of additional functions - MRI-compatible and 
home monitoring function. Methods: The literature review of the efficacy and 
safety «MRI-compatible CD with home monitoring» were conducted on the database 
of the Cochrane Library, a database of bibliographic review on the effectiveness of 
medical intervention (DARE), database reviews of health technology assessment 
(HTA), PubMED, CADTH, NICE, Clinical Trials and TripDatabase. Results: Search 
results revealed 522 publications, and from this number 3 studies were selected 
for the final analysis. The remaining works were excluded due to non-compliance 
to the PICOS’ criteria. According to the data from representatives Biotronik and 
Medtronic in Kazakhstan the CD’s cost without MRI-compatible, completed with 
electrodes in Kazakhstan ranges $18.000-19.000. ConClusions: Application in 
clinical practice, MRI-compatible CD with home monitoring has significant advan-
tages - the almost complete absence of the risk of adverse events, the possibility 
of more frequent MRI as one of the main methods of diagnosis and early detection 
of various pathological conditions, the avoidance of unnecessary visits to patients 
without necessary evidence, revealing significant changes in the health status of 
patients in the constant monitoring; has a relatively small increase in the cost of a 
complete set of MRI-compatible CD with home monitoring in comparing with the 
cost of a set of CD without this function, an average of 33%.
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objeCtives: Major depressive disorder (MDD) is a debilitating disease that signifi-
cantly decreases quality of life. Repetitive Transcranial Magnetic Stimulation (rTMS) 
therapy is a safe, non-invasive, physical treatment for major depressive disorder. 
We evaluated the cost-effectiveness of rTMS compared with third-line antidepres-
tiveness of 24-hours Holter and up to 30 days ELR, each with different diagnostic 
yield, compliance, and costs in patients with syncope in Colombia. Methods: An 
analytical decision tree model was constructed including diagnostic yield, patient 
compliance, mortality rate, QALYs, associated costs to diagnosis and not having 
a diagnosis. Third party payer perspective, five year horizon and 3.5% discount 
rate for utilities and costs were assumed. Patient pathways and model inputs were 
ascertained from doctor interviews and literature search. Average market prices of 
US$175 for 24-hours Holter and US$627 for ELR were used. Micro-costing for avoided 
emergency visits and hospitalizations was done via Colombian key opinion leader 
interviews and official tariffs for costs of not having a diagnosis along five years. 
Uncertainty adjustments were done when judged appropriate. Incremental Cost 
Effectiveness ratio (ICER) was done, incorporating deterministic and probabilistic 
sensitivity analyses. Results: 24-Holter strategy had 19% diagnosis yield compared 
to 63% for ELR. Over a five year horizon, ELR strategy obtained more QALYs than 
24-Holter (2.62 vs. 2.18), at lower cost, been dominant over 24-hours Holter with 
US$2,165.6 incremental savings per incremental QALY. Sensitivity analysis showed 
the result to be particularly sensitive to disease and untreated syncope utilities 
and cost. The probabilistic sensitivity analysis showed a robust model with 95% 
confidence intervals of 1.83–2.57 QALYs for 24-hours Holter and 2.21–3.04 QALYs 
for ELR. ConClusions: Over a 5 year horizon, the ELR with greater utility (QALY) 
to lower costs, as demonstrated through greater incremental savings per QALY, was 
dominant over 24-Holter. The superior results of the ELR are attributable in part to 
the greater diagnostic yield and higher patient compliance.
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objeCtives: Drug-eluting stents (DESs) have been shown to reduce in-stent reste-
nosis and target vessel revascularization (TVR) in several large clinical trials. We 
conducted this study to explore the differences in the cost and clinical outcome 
of DESs and bare metal stents (BMSs). Methods: We retrospectively analyzed the 
clinical data and costs of patients with stable angina treated with coronary stents in 
2012 at a medical center in Taiwan. Results: We enrolled 245 patients treated with 
DESs and 194 patients treated with BMSs. The use of DESs is a lower rate of TVR com-
pared with that with BMSs (11% vs. 20%, p = 0.015). Compared with the DES group, 
the overall costs were significantly higher in the BMS group (NT$237727.0±89714.9 
vs. NT$187017.3±129713.5, p < 0.001). ConClusions: The use of DESs reduces the 
rate of TVR at 2 years after intervention, but is probably not cost-effective compared 
with BMSs in patient.
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objeCtives: To perform a full economic evaluation through a cost-effectiveness 
analysis of the use of paclitaxel-eluting balloon catheter (IN.PACT™ Admiral) in 
comparison with balloon catheter, for PTA in the treatment of peripheral obstruc-
tive artery diseases in Mexican population, from the perspective the public health 
care system in Mexico. Methods: The measure of effectiveness considered was 
decrease in the rate of target lesion revascularization (TLR). Information about effi-
cacy and safety of the intervention was obtained from a systematic review. Direct 
medical costs were considered (cost of devices as well as the procedure). An incre-
mental cost-effectiveness analysis was performed with a horizon of two years. To 
demonstrate the robustness of the model, univariate sensitivity analysis and proba-
bilistic sensitivity analysis were executed using Monte Carlo simulations. Results: 
Paclitaxel-eluting balloon catheter for PTA (IN.PACT™ Admiral) demonstrated good 
efficacy and safety producing a significant reduction in TLR at six months, which 
was maintained up to 24 months (estimated rate 14.4%), evaluated angiographi-
cally. This was significantly better than that obtained with conventional balloon 
angioplasty (estimated rate 40.3%) in the treatment of restenosis. Total average 
costs were $102,299.00 and $115,652.00 respectively. Therefore the incremental 
cost-effectiveness ratio (ICER) obtained showed that the paclitaxel-eluting balloon 
catheter for PTA (IN.PACT™ Admiral) is a dominant option. Clinical benefits were 
clearly demonstrated by the improvement in the ankle-arm index and Rutherford 
category. ConClusions: Paclitaxel-eluting balloon catheter for PTA (IN.PACT™ 
Admiral) proved to be more effective and less costly than the standard of care in 
the treatment of peripheral obstructive arterial disease, for Mexican public health 
care institutions.
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objeCtives: To develop cost-analysis of MEDIHONEY CALCIUM ALGINATE 
(MEDIHONEY) versus ACQUACEL AG (AG) dressings for chronic-wound treatment in 
adults, from perspective of Brazilian public payers. Methods: Data from Brazilian 
Hospital Information System from October 2013 to September 2014 was used to 
define the annual number of hospital admissions due to chronic wounds (only 
non-surgical records with L97.909 ICD-10 code included). The model assumed that 
patients are discharged at the time their wounds heal. No critically ill patients 
in ICUs were included. Only patients above 20 years old were included. Unit cost 
